Coleen K Cunningham MD (She/Her)

Professor and Chair Pediatrics University of California, Irvine, Senior VP and Pediatrician in Chief, Children's Hospital of Orange County (CHOC)

Join to View Full Profile

101 The City Dr SOrange, CA 92868
Phone+1 714-880-7812
Fax+1 714-285-0389

Education & Training

SUNY Upstate Medical UniversityFellowship, Pediatric Infectious Diseases, 1988 - 1991
SUNY Upstate Medical UniversityResidency, Pediatrics, 1985 - 1989
SUNY Upstate Medical UniversityClass of 1985

Certifications & Licensure

CA State Medical License 2021 - 2027
NC State Medical License 2003 - 2021
American Board of Pediatrics Pediatric Infectious Diseases

Awards, Honors, & Recognition

Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
Completed
Phase 1
Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths Start of enrollment: 2004 Feb 01
Completed
Phase 2
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women Start of enrollment: 2010 Jan 01
Completed
Phase 4
IMPAACT P1074: Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents Start of enrollment: 2009 Mar 01
Completed
IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents Start of enrollment: 2010 Oct 08
Completed
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children Start of enrollment: 2010 Dec 01
Completed
Phase 1
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants Start of enrollment: 2013 Aug 26
Terminated
Phase 2, Phase 3
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age Start of enrollment: 2019 Jun 20
TERMINATED
PHASE1, PHASE2
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Start of enrollment: 2013 Oct 03
Completed
Phase 1
Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1.
Coleen K Cunningham, Elizabeth J McFarland, Petronella Muresan, Edmund V Capparelli, Charlotte Perlowski
Journal of the Pediatric Infectious Diseases Society. 2025-02-06
Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens.
Christopher Alba, Shelly Malhotra, Stephanie Horsfall, Matthew E Barnhart, Adrie Bekker
Plos One. 2025-01-01
Mental health challenges and perceptions of stigma among youth living with HIV in Tanzania.
Laura S Mkumba, Fortunata Nasuwa, Blandina T Mmbaga, Aisa M Shayo, Coleen K Cunningham
Plos One. 2025-01-01

Journal Articles

Development and Application of a Multiplex Assay for the Simultaneous Measurement of Antibody Responses Elicited by Common Childhood Vaccines
Elizabeth J McFarland, Coleen K Cunningham, William Borkowsky, Sallie R Permar, ScienceDirect

Press Mentions

CHOC Earns National Distinction as Batten Disease Center of ExcellenceAugust 12th, 2024
RSV Vaccine Trials Show Critical Protection in Newborn's First MonthsApril 18th, 2023
Pfizer RSV Vaccine Trials Show Protection for Infants and Older AdultsApril 7th, 2023
Join now to see all